Stock search

Ticker or company name

Pfizer

PFE · NYSE · Pharmaceuticals

$28,86Down −0,03 (−0,10%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$166 bn
Div. yield
5,4%
Year to date
+16,0%
52 weeks: $23,62$31,44

Ratio score

44/100
Ratio would watch

based on 8 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

2 ✓ · 3 — · 3 ✕ · 2 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM40,816,241,8
Forward P/E10,5—12,4
PEG−5,5—3,3
P/S2,62,63,4
EV/EBITDA24,014,224,0
P/FCF14,0—14,0
P/B1,91,88,1

Industry median — across 6 profitable companies in “Pharmaceuticals” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 34 analysts

Buy
13
Hold
18
Sell
3

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20260,740,87Up +17,6%
Q2 20260,690,77Up +11,4%
Q1 20260,720,75Up +3,5%
Q4 20250,580,66Up +14,3%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue16,6 bn15,0 bn14,5 bn17,6 bn16,7 bn14,7 bn13,7 bn17,8 bn17,7 bn13,3 bn14,9 bn14,2 bn
EPS0,56−0,040,47−0,290,620,510,520,070,780,010,55−0,59
Margin19,6%−1,6%18,6%−9,4%21,3%19,9%21,6%2,3%25,2%0,3%20,9%−23,6%
FCF4,80 bn302 m2,18 bn4,50 bn4,00 bn−1,20 bn1,77 bn5,80 bn6,06 bn−2,42 bn386 m4,20 bn

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: purchases $2,96 m (3 people), sales $134 661.

NameAmountSharesPrice
bourla albert12 Aug 2026 · open-market purchase$1,00 m38 000$26,34
damico jennifer b.5 Aug 2026 · sale$83 2613 278$25,40
buckley mortimer j5 Aug 2026 · open-market purchase$960 36937 632$25,52
blaylock ronald e5 Aug 2026 · open-market purchase$998 82139 231$25,46
damico jennifer b.9 Jun 2026 · sale$51 4002 000$25,70

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Pharmaceuticals
Exchange
NYSE
Country
US
IPO date
17 Jan 1944

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
BMYBristol Myers Squibb$62,9381would consider14,0+4,2%18,5%
MRKMerck & Co.$144,4638would not consider148,5+4,9%3,6%
JNJJohnson & Johnson$282,5544would watch42,9+7,8%16,2%
ZTSZoetis$84,3975would consider12,4+1,2%26,1%
VTRSViatris$20,7436would not consider—+4,3%—
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.